* If you want to update the article please login/register
Samples will be quickly transported to a lab in which T-cell and immunoglobulin G4 signatures for the full 18 food panel will be analyzed immediately. Participants would be offered a sham diet if they were randomized to the sham diet. Selecting a random number of foods from a random list of the potential rejected foods will result in a healthy number of foods being introduced. Participants will consult with a study dietician to determine their baseline food intake and recommended diet intervention after being assigned to a diet intervention. Following completion of the iDIET research, participants treated with the immune-signature diet will have significantly lower post-treatment eosinophil counts and dysphagia symptom scores than those on a sham diet. 1 After completion of the study, participants will return to normal care of their disease, including diet re-introduction.
Source link: https://clinicaltrials.gov/ct2/show/NCT05543512
Bakground: Intralymphatic immunotherapy has been developed as a new, more effective, modeality for allergy immunotherapy. To stimulate the immune system, ultrasound-guided injections into the lymph node are delivered directly into the secondary lymphoid organ. Methods: 52 patients who had previously participated in the RDBPC trial were invited to participate in this open follow-up.
Source link: https://clinicaltrials.gov/ct2/show/NCT04296474
In the case of a reaction, the current remedy for food allergy is to avoid eating the foods that can cause an allergic reaction and have medications such as epinephrine. People with multiple food allergies eat foods to which they are allergic, according to the investigators in this report. After taking it for a long time, there are three stages to the study: If omalizumab stops or reduces allergic reactions to peanut and other common food allergens after taking it for a long time. Investigate Responses In Stage 2: How a short course of omalizumab in collaboration with Multi-allergen OIT aids in reducing allergic reactions.
Source link: https://clinicaltrials.gov/ct2/show/NCT03881696
Obtaining a blood sample from the patient to create a pool of sera for the "in vitro" standardization of the allergenic extract. Each serum sample will be stored in a tube that will be identified with the subject number and frozen and frozen. These serum samples will remain in the freezer until the investigation is complete. When the research is finished, the sera will be taken to the lab, where all sera will be pooled. The complementary in vitro standardization tests will be carried out using this 'pool'' of sera. The Royal Spanish Pharmacopoeia and the European Pharmacopoeia are mixed together to create a pool that will be used, as shown in the previous paragraph, in all the in vitro tests that are used to standardize and characterize this extract and produce its corresponding HIRP. The original serum samples' tubes are destroyed once the pool has been established.
Source link: https://clinicaltrials.gov/ct2/show/NCT05532566
Obtaining a blood sample from the patient to create a pool of sera for the "in vitro" standardization of the allergenic extract. Each serum sample will be stored in a tube labelled with the subject number and frozen. These serum samples will remain in the freezer until the conclusion of the study. Once the pool has been established, the original serum samples' tubes are destroyed.
Source link: https://clinicaltrials.gov/ct2/show/NCT05533385
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions